Aradigm

Leadership

Pioneering Advancements in the Pulmonary
Pharmaceutical Industry

Aradigm's team represents a rare combination of multidisciplinary expertise and has experience bringing a variety of pharmaceutical and health care products to market in the U.S. and internationally. Members of the Company's Scientific Advisory Board are among the world's leading experts in pulmonary medicine. Together, this leadership team is pioneering important advancements in the pulmonary pharmaceutical industry and positioning Aradigm as a new leader in the specialty pharmaceutical market.

Executive Management

		Igor Gonda, Ph.D. President & Chief Executive Officer Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

		Nancy Pecota Chief Financial Officer Ms. Pecota has more than 20 years of experience in corporate accounting and operations management. She previously served as Chief Financial Officer for NuGEN Technologies, Inc., a life sciences tools company that provides specialty reagents to pharmaceutical and diagnostics companies. Prior to that she served as a financial consultant to early- and mid-stage life sciences companies, developing fundable business models and assessing and improving internal financial preparation and reporting processes. She has served as Vice President, Finance and Administration at Signature BioScience, Inc., a venture-backed biopharmaceutical company; and as Director, Finance and Accounting for ACLARA BioSciences, Inc., a biotechnology company. Ms. Pecota holds a Bachelor of Science in Economics from San Jose State University and was among the executives named in the San Francisco Business Times "100 Most Influential Bay Area Business Women" in 2002 and 2003.

		D. Jeffery Grimes, J.D./M.B.A. Vice President, Legal Affairs, General Counsel & Secretary Mr. Grimes has served as our General Counsel & Corporate Secretary since June 2007. From May 2005 to June 2007, Mr. Grimes was an attorney in the Trademark & Brands department at Intel Corporation’s headquarters in Santa Clara, CA. From May 2002 to January 2005, Mr. Grimes was Assistant General Counsel at Connetics Corporation, a publicly-traded specialty pharmaceutical company focused on dermatology, located in Palo Alto, CA. From February 2000 to April 2002, Mr. Grimes was Vice President, Corporate Counsel & Secretary of GN ReSound, Inc. and Beltone Electronics Corporation, both subsidiaries of a Danish-based multinational leading medical device company for hearing devices, reporting at various times during his tenure in Copenhagen, Denmark; Redwood City, CA; and Chicago, IL. Prior to becoming in-house counsel, Mr. Grimes was a commercial litigator for seven years. Mr. Grimes holds J.D./M.B.A. degrees and a B.S. in Finance from University of Colorado, Boulder. Mr. Grimes is a member of the Biotechnology Industry Organization – General Counsel Committee.

Board of Directors

Virgil D. Thompson
Chairman of the Board, Aradigm Corporation

Frank H. Barker
Former Group Chairman, Johnson & Johnson

Igor Gonda, Ph.D.
President & Chief Executive Officer, Aradigm Corporation

Dr. John M. Siebert
Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs

Scientific Advisory Board
Aradigm's Scientific Advisory Board is a highly regarded team of scientific experts who help the Company with strategic input into the development of treatments for severe respiratory disease, hormonal and metabolic disorders, and in pharmaceutical development and pulmonary drug delivery in general. The group assists the Company on a variety of issues related to potential product applications, product development paths and clinical testing.

Peter R. Byron, Ph.D.
Medical College of Virginia, Virginia Commonwealth University. Area of expertise: Aerosol Science/ Pharmaceutics

Peter S. Creticos, M.D.
The Johns Hopkins University School of Medicine
Area of expertise: Allergy/Immunology/Asthma

Stephen J. Farr, Ph.D.
Zogenix, Inc. Area of expertise: Pulmonary Delivery/Pharmaceutics

Phyllis Gardner, M.D.
Stanford University. Area of expertise: Clinical Pharmacology/Drug Development

Michael Konstan, M.D.
Rainbow Babies and Children’s Hospital. Area of expertise: Pulmonary Disease/Cystic Fibrosis

Michael Powell, Ph.D.
Sofinnova Ventures. Area of expertise: Drug Development

Adam Wanner, M.D.
University of Miami. Area of expertise: Chronic Obstructive Pulmonary Disease (COPD)

Martin Wasserman, Ph.D.
Roche, AtheroGenics (retired). Area of expertise: Asthma

Tunde Otulana , M.D.
Dr. Otulana, a practicing pulmonologist, was the Senior Vice-President, Development and Chief Medical Officer at Aradigm until Dec 2008. He had joined Aradigm in October 1997 as the Vice President of Clinical & Regulatory Affairs.

From 1991 to 1997, Dr. Otulana was a medical officer and clinical team leader in Pulmonary Drug Products at the Center for Drug Evaluation and Research of the FDA. He was responsible for or participated in the FDA review and approval of major asthma drugs currently marketed in the US as well as major FDA initiatives in the pulmonary drug area. He obtained his M.D. degree at University of Ibadan, Nigeria and completed training in Internal Medicine at the University College Hospital, Ibadan, and in pulmonary medicine at Papworth Hospital, Cambridge, England and Howard University Hospital, Washington, DC.

Dr. Otulana served on the FDA's Anesthesiology and Respiratory Therapy Devices Advisory Committee for 4 years ending November 2005. He serves on the Editorial Board of the Journal of Aerosol Medicine and he is an Editorial Reviewer for Chest. He is a member of United Nations Environmental Program (UNEP) Aerosol Technical Options Committee charged with overseeing the phase-out of CFCs under the Montreal Protocol. Dr. Otulana is an Associate Clinical Professor in Pulmonary and Critical Care Medicine, University of California, Davis, where he teaches and also runs an outpatient chest clinic. He is an author on many original scientific publications.

In addition to this Scientific Advisory Board, the Company also engages other scientific and medical experts to assist on issues specific to particular indications and programs.

CONTACT NEWS & EVENTS LEGAL SITE MAP